As expected, the combination therapy further enhanced tumor immune infiltration in distant tumors compared with anti-PD-1 therapy alone, despite no statistically significant difference was observed when compared with ZD55-IL-24 therapy alone (Fig. 4d, h), which was in line with the observation in local tumors. This evidence concerns the gene PDCD1 and neoplasm.